Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2023-01-01 DOI:10.22514/ejgo.2023.081

{"title":"Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro","authors":"","doi":"10.22514/ejgo.2023.081","DOIUrl":null,"url":null,"abstract":"Endometrial cancer (EC) includes several epithelial malignancies existed in the endometrium tissues. To improve the prognosis of EC, it is greatly needed to find new drugs. Dezocine, a organic compound, is an κ agonist and a µ receptor antagonist, is used in clinical anesthesia after cancer surgery with few side effects, and its anti-tumor effects have also been demonstrated in several tumors. However, the effects of Dezocine on EC progression have not been elusidated. Herein, we investigated the role of Dezocine in EC cell functions. Through a series of cellular assays, such as cell counting kit-8 (CCK-8), flow cytometry (FCM), transwell assays, we found that Dezocine suppressed the EC cell proliferation, and stimulated EC cell apoptosis in vitro. Furthermore, results revealed Dezocine restrained the motility, including migration and invasion of EC cells. Mechanically, Dezocine suppressed the Akt (protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway in EC cells, thereby suppressing EC cell proliferation as well as migration in vitro. In conclusion, Dezocine inhibits proliferation as well as migration of EC in vitro.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22514/ejgo.2023.081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Endometrial cancer (EC) includes several epithelial malignancies existed in the endometrium tissues. To improve the prognosis of EC, it is greatly needed to find new drugs. Dezocine, a organic compound, is an κ agonist and a µ receptor antagonist, is used in clinical anesthesia after cancer surgery with few side effects, and its anti-tumor effects have also been demonstrated in several tumors. However, the effects of Dezocine on EC progression have not been elusidated. Herein, we investigated the role of Dezocine in EC cell functions. Through a series of cellular assays, such as cell counting kit-8 (CCK-8), flow cytometry (FCM), transwell assays, we found that Dezocine suppressed the EC cell proliferation, and stimulated EC cell apoptosis in vitro. Furthermore, results revealed Dezocine restrained the motility, including migration and invasion of EC cells. Mechanically, Dezocine suppressed the Akt (protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway in EC cells, thereby suppressing EC cell proliferation as well as migration in vitro. In conclusion, Dezocine inhibits proliferation as well as migration of EC in vitro.

查看原文本刊更多论文

地佐辛在体外抑制子宫内膜癌的增殖和迁移

子宫内膜癌(EC)包括存在于子宫内膜组织中的几种上皮恶性肿瘤。为了改善EC的预后，迫切需要寻找新的治疗药物。Dezocine是一种有机化合物，是一种κ受体激动剂和µ受体拮抗剂，用于癌症手术后的临床麻醉，其副作用很少，其抗肿瘤作用也已在几种肿瘤中得到证实。然而，地佐辛对EC进展的影响尚未明确。在此，我们研究了Dezocine在EC细胞功能中的作用。通过细胞计数试剂盒-8 (CCK-8)、流式细胞术(FCM)、transwell等一系列细胞实验，我们发现地佐辛在体外抑制EC细胞增殖，刺激EC细胞凋亡。此外，研究结果显示，地佐辛抑制了EC细胞的运动，包括迁移和侵袭。机械上，Dezocine抑制EC细胞中Akt (protein kinase B, PKB)/哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)通路，从而抑制EC细胞体外增殖和迁移。综上所述，地佐辛在体外可抑制EC的增殖和迁移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.